Kirr Marbach & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kirr Marbach & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-93,728	Closed	-$10.7M	–	50
2022 Q4	$10.7M	Sell	93,728 -2,155	-2%	-$179K	3.33%	13
2022 Q3	$5.93M	Sell	95,883 -366	-0.4%	-$25.6K	2.01%	21
2022 Q2	$7.68M	Sell	96,249 -77	-0.1%	-$7.29K	2.41%	17
2022 Q1	$10.1M	Buy	96,326 +1,114	+1%	+$109K	2.73%	14
2021 Q4	$10.3M	Buy	95,212 +479	+0.5%	+$52.3K	2.71%	14
2021 Q3	$10.4M	Buy	94,733 +2,156	+2%	+$224K	3.04%	12
2021 Q2	$8.67M	Buy	92,577 +42,577	+85%	+$3.92M	2.46%	20
2021 Q1	$4.6M	Buy	+50,000	New	+$4.22M	1.33%	33

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kirr Marbach & Co's HZNP Position: Q1 2023 in Review

Kirr Marbach & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 93,728 shares — an estimated $10.7M sold.

Kirr Marbach & Co first reported a position in HZNP in Q1 2021 and held it in 8 quarters. The position peaked at $10.7M in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Kirr Marbach & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Kirr Marbach & Co sold 93,728 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $10.7M.
Kirr Marbach & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 8 quarters.
Kirr Marbach & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10.7M in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Kirr Marbach & Co's 13F filing for Q1 2023, filed 17 Apr 2023.